☰

Jay K. Wathen, Ph.D. - Publications

Affiliations: 
2005 The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Statistics, Biostatistics Biology
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Wathen JK, Thall PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clinical Trials (London, England). 14: 432-440. PMID 28982263 DOI: 10.1177/1740774517692302  0.651
2015 Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. PMID 26710211 DOI: 10.1002/cncr.29858  0.364
2015 Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1621-8. PMID 25979922 DOI: 10.1093/annonc/mdv238  0.639
2014 Morgan CC, Huyck S, Jenkins M, Chen L, Bedding A, Coffey CS, Gaydos B, Wathen JK. Adaptive Design: Results of 2012 Survey on Perception and Use Therapeutic Innovation and Regulatory Science. 48: 473-481. DOI: 10.1177/2168479014522468  0.368
2011 Lionberger JM, Dorcy KS, Dean C, Holm N, Scott BL, Wathen JK, Estey EH, Pagel JM. Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML Blood. 118: 1552-1552. DOI: 10.1182/blood.v118.21.1552.1552  0.421
2010 Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4884-91. PMID 20724445 DOI: 10.1158/1078-0432.CCR-10-1177  0.343
2008 Wathen JK, Thall PF. Bayesian adaptive model selection for optimizing group sequential clinical trials. Statistics in Medicine. 27: 5586-604. PMID 18752257 DOI: 10.1002/sim.3381  0.562
2008 Thall PF, Wathen JK. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Current Opinion in Oncology. 20: 407-11. PMID 18525336 DOI: 10.1097/CCO.0b013e328302163c  0.626
2008 Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Statistics in Medicine. 27: 2802-15. PMID 17948869 DOI: 10.1002/sim.3109  0.651
2007 Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2755-63. PMID 17602081 DOI: 10.1200/JCO.2006.10.4117  0.576
2007 Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. European Journal of Cancer (Oxford, England : 1990). 43: 859-66. PMID 17306975 DOI: 10.1016/j.ejca.2007.01.006  0.626
2007 Thall PF, Cheung YK, Inoue LYT, Wathen JK. Comments on 'Continuous Bayesian adaptive randomization based on event times with covariates' [4] Statistics in Medicine. 26: 3052-3054. DOI: 10.1002/Sim.2762  0.504
2006 Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, Priebat DA, Meyers PA, Benjamin RS, Baker LH. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 9515. PMID 27952837 DOI: 10.1200/jco.2006.24.18_suppl.9515  0.339
2006 Maki RG, Hensley ML, Wathen JK, Patel SR, Priebat DA, Okuno S, Reinke D, Thall PF, Benjamin RS, Baker LH. A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 9514. PMID 27952836 DOI: 10.1200/jco.2006.24.18_suppl.9514  0.458
2006 Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Statistics in Medicine. 25: 55-70. PMID 16025549 DOI: 10.1002/Sim.2247  0.654
2006 Wathen JK, Christen JA. Implementation of backward induction for sequentially adaptive clinical trials Journal of Computational and Graphical Statistics. 15: 398-413. DOI: 10.1198/016214506X113406  0.462
2005 Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine. 24: 1947-64. PMID 15806621 DOI: 10.1002/sim.2077  0.624
2003 Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine. 22: 763-80. PMID 12587104 DOI: 10.1002/sim.1399  0.597
Show low-probability matches.